We surface new signals, evaluate the evidence, and track what's moving in the field so you can focus on what's real.
Evidence tags: Strong = human signal with controls · Moderate = promising but limited
How we rate evidence →No strong human evidence shows that BPC-157 heals tendon or ligament injuries. Most support is animal, cell or mechanism-based, and internet recovery claims should not be treated as proven clinical benefit.
TB-500 injury-recovery claims are not supported by strong human clinical evidence. The claim often relies on extrapolation from thymosin beta-4 biology and should be treated as unproven.
Semax has been discussed in non-US medical and research contexts, but that does not prove it improves cognition in healthy people. Healthy-user nootropic claims remain unproven.
Rapamycin has unusually strong aging-biology interest, but it is not proven to slow human aging or extend lifespan in healthy adults. Off-label longevity use remains a medical decision, not a protocol from an article.
NMN may affect NAD-related biomarkers in some studies, but that does not prove it slows human aging. The stronger claim needs clinical outcomes, not only a molecule-level signal.
Partial reprogramming is one of the most important frontier ideas in aging biology, but it has not been proven to reverse human aging.
No dosing calculators, cycle builders or personalized medical instructions.
Claim pages separate editorial verdicts from paid services and telehealth incentives.
Commercial incentives are labeled instead of hidden inside wellness copy.
Community chatter can explain demand, but source cards carry the evidence load.
Plain-English verdicts explain what the source does and does not prove.
Automation helps triage claims; high-risk pages are flagged for review.
DEEP DIVE
The short answer is no for consumer longevity or injury claims; verify any product-specific claim against official FDA records.
EXPLAINER
BPC-157 has animal and mechanism-heavy discussion, but that is not the same as strong human injury evidence.
TREND REPORT
TB-500 is usually marketed as a peptide fragment related to thymosin beta-4, but naming can blur important evidence and quality questions.
DATA NOTE
Compounding can be lawful in some circumstances, but compounded drugs themselves are not FDA-approved products.
| Tracker | What it tracks | Signals (7d) | Evidence mix (7d) | Trend (30d) | Last updated |
|---|---|---|---|---|---|
| ♡Senolytics | Compounds and approaches targeting senescent cells | 12 | 25%50%17%8% | 2h ago | |
| ♡mTOR Pathway | Inhibitors and modulators of mTOR signaling | 9 | 22%44%22%12% | 3h ago | |
| ♡NAD+ Modulators | Compounds affecting NAD+ metabolism | 7 | 14%45%29%14% | 5h ago | |
| ♡Epigenetic Reprogramming | Approaches targeting epigenetic age | 6 | 17%33%33%17% | 6h ago |
We apply a consistent methodology to separate signal from noise.
We scan high-quality sources and preprints for new claims and data.
We assess study design, sample size, controls, replication, and bias.
We assign an evidence tag and explain our reasoning.
We monitor claims over time as new data emerges.
A concise, high-signal briefing delivered every Saturday.